Cara Therapeutics, a Phase 3-stage biotech developing a novel opioid pain medication, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Cara Therapeutics plans to list on the NASDAQ under the symbol CARA. Cara Therapeutics initially filed confidentially on 10/4/2013. Stifel and Piper Jaffray acted as joint bookrunners on the deal.
